Crossmark

Nonalcoholic Fatty Liver Disease and Obesity Treatment

Crossref DOI link: https://doi.org/10.1007/s13679-019-00345-1

Published Online: 2019-04-03

Published Print: 2019-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Brunner, Katherine T.

Henneberg, Cameron J.

Wilechansky, Robert M.

Long, Michelle T.
Funding

Funding for this research was provided by:

School of Medicine, Boston University (UL1 TR001430)

National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK113252)
License Information

Text and Data Mining valid from 2019-04-03
More Information

Article History

First Online: 3 April 2019

Compliance with Ethical Standards

:

: Katherine T. Brunner declares that she has no conflict of interest.Cameron J. Henneberg declares that he has no conflict of interest.Robert M. Wilechansky declares that he has no conflict of interest.Michelle T. Long has received research funding from Echosens Corporation.

: This article does not contain any studies with human or animal subjects performed by any of the authors.